The challenges of COVID-19 Delta variant: Prevention and vaccine development

Xuemei He1 | Cai He1 | Weiqi Hong1 | Kang Zhang2 | Xiawei Wei1

1 Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, P. R. China
2 Center for Biomedicine and Innovations, Faculty of Medicine, Macau University of Science and Technology, Taipa, Macau, P. R. China

Correspondence
Kang Zhang, Center for Biomedicine and Innovations, Faculty of Medicine, Macau University of Science and Technology, Taipa, Macau, P. R. China.
Email: kang.zhang@gmail.com
Xiawei Wei, Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu, Sichuan 610041, P. R. China.
Email: xiaweiwei@scu.edu.cn

Xuemei He and Cai He contributed equally to this work.

Funding information
the Excellent Youth Foundation of the Sichuan Scientific Committee Grant in China, Grant/Award Number: 2019JDJQ0068; National Natural Science Foundation Regional Innovation and Development, Grant/Award Number: U19A2003; the National Natural Science Foundation of China, Grant/Award Number: 81800421

Abstract
Several SARS-CoV-2 variants have emerged since the pandemic, bringing about a renewed threat to the public. Delta variant (B.1.617.2) was first detected in October 2020 in India and was characterized as variants of concern (VOC) by WHO on May 11, 2021. Delta variant rapidly outcompeted other variants to become the dominant circulating lineages due to its clear competitive advantage. There is emerging evidence of enhanced transmissibility and reduced vaccine effectiveness (VE) against Delta variant. Therefore, it is crucial to understand the features and phenotypic effects of this variant. Herein, we comprehensively described the evaluation and features of Delta variant, summarized the effects of mutations in spike on the infectivity, transmission ability, immune evasion, and provided a perspective on efficient approaches for preventing and overcoming COVID-19.

KEYWORDS
Delta variant, mutation, SARS-CoV-2, spike, vaccine

1 | EMERGENCE OF SARS-COV-2 B.1.617 LINEAGES

Coronavirus disease 2019 (COVID-19) is a highly contagious viral disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).1 As of September 4, 2021, this pandemic has resulted in 4.5 million deaths worldwide according to the World Health Organization (WHO) (https://www.who.int/). With the joint efforts of the global community, vaccine protection and effective supervision of SARS-CoV-2 positive individuals greatly reduced COVID-19 hospitalizations and deaths. However,
in recent months when B.1.617 lineages, especially B.1.617.2 variant (also named Delta) rapidly spread, even though more than five billion vaccine doses have been administered globally (https://www.who.int/), thousands of new cases are diagnosed every day. Therefore, it is necessary to have a more detailed understanding of the SARS-CoV-2 Delta variant.

As a typical RNA virus, the pace of mutation is about $10^{-4}$ replacement per site for every year.2,3 The genome of SARS-CoV-2 is relatively unstable compared to other RNA viruses.2 The mutations in the genome lead to modifications in phenotype including different antigens, changes in transmissibility or virulence. Variants with higher transmissibility and infectivity, drug resistance, or immune evasion are more likely to be preserved in the selection. Therefore, several SARS-CoV-2 variants have emerged to replace the pre-existing SARS-CoV-2 variants and spread globally. With competitive advantages over their ancestors, the variants tend to be dominant in many cases. Until now, the existing variants have been designated as variants of concern (VOC) and variants of interest (VOI) by WHO. VOC contains Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2) variants (Figure 1) and their sublineages while VOI contains B.1.525 (Eta), B.1.526 (Iota), B.1.617.1 (Kappa), C.37 (Lambda), and B.1.621 (Mu) variants (https://www.who.int/en/activities/tracking-SARS-CoV-2-variants). By August 24, 2021, cases infected by Alpha, Beta, Gamma, and Delta variants have been reported in 192, 141, 86, and 163 countries, respectively (https://apps.who.int/iris/bitstream/handle/10665/344560/CoV-weekly-itrep24Aug21-eng.pdf?sequence=1&isAllowed=y).

In early 2021, the variant responsible for the outbreak of COVID-19 in India was initially called “double mutant” due to E484Q and L452R mutations in spike.4 This name “double mutant” was soon modified as B.1.617 since it had a group of sequence clusters with common L452R, D614G, and P681R mutations.5,6 Notably, the B.1.617 lineages are not homogeneous. Some multiple mutations, such as T19R, G142D, or D950N, frequently appear together in a lineage and also can be detected in other sublineages at a lower frequency.7 With the sequencing of these variants, the first sequence cluster was identified in India carrying T19R, G142D, L452R, E484Q, D614G, and P681R mutations.5,6 Notably, the B.1.617 lineages are not homogeneous. Some multiple mutations, such as T19R, G142D, or D950N, frequently appear together in a lineage and also can be detected in other sublineages at a lower frequency.7 With the sequencing of these variants, the first sequence cluster was identified in India carrying T19R, G142D, L452R, E484Q, D614G, and P681R, and D950N substitutions in spike.5 The emergence of Q1071H mutation produced the B.1.617 lineages variants into three new...
subclusters, and the first identified sublineage was B.1.617.1 variant (Kappa), followed by B.1.617.2 variant (Delta) and B.1.617.3 variant.\textsuperscript{5,6} B.1.617.1 variant was reclassified to a VOI by WHO on April 4, 2021, because of its increased transmissibility, but the global prevalence seemed to be declined. Delta variant was first detected in October 2020 in India and further determined in March 2021 in the United States.\textsuperscript{9} In India, it spread rapidly and the proportion of Delta variant in all sequenced samples increased from 4.0\% on March 8, 2021 to 30.4\% on March 29, 2021 according to GISAID (www.gisaid.org). The WHO classified the Delta variant as a VOI on April 4, 2021. Later, because of its astonishing transmissibility and infectivity, the Delta variant displaced other pre-existing lineages and its percentage in all circulating viruses significantly raised to 89.8\% on May 10, 2021 among sequences in India (www.gisaid.org). Delta variant caused 17 million COVID-19 patients including reinfections during March-May 2021.\textsuperscript{9} These results prompted the WHO to classify it as a VOC on May 11, 2021. Presently, B.1.617.3 is neither a VOC nor a VOI because of its low prevalence. In short, the B.1.617 and its sublineages are mainly responsible for the second wave of infections in India, resulting in more than 30 million COVID-19 patients and 4,00,000 deaths in India alone.\textsuperscript{10}

2 \ THE FEATURES OF COVID-19 CAUSED BY DELTA VARIANT

The reproductive number (R0) of SARS-CoV-2 wild type has been estimated to be as high as 2.3-5.7 (Figure 2A)\textsuperscript{11,12} Significantly, recent studies have revealed the R0 of Delta variant is up to 5-8, higher than Alpha, Beta, and Gamma variants about 55\% (95\% CI: 43–68), 60\% (95\% CI: 48–73), and 34\% (95\% CI: 26–43), respectively,\textsuperscript{9,13–15} indicating its prominent transmissibility. The Delta variant has replaced the pre-existing lineages and has become the most dominant variant in India and further spreads to 163 countries within a few months. When India was struggling against COVID-19 cases, a traveller returned from India resulted in 77\% of sequenced circulating viruses identified as Delta variant between June 2 and 9 in the United Kingdom where Alpha variant was initially prevalent.\textsuperscript{7} Meanwhile, the transmission advantage of the Delta variant estimated in France is 79\% higher than Alpha variant.\textsuperscript{16} As of the early of August 2021, the proportion of Delta variant in circulating virus sequences also accounts for more than 90\% over the world (www.gisaid.org), which triggers a new wave of global infection. The life cycle of the Delta variant in host cells is shown in Figure 2B. The mutant spike of the Delta variant mediates more efficient cell entry and enhanced syncytium formation, which probably implicates high virus load and severe disease.\textsuperscript{17} Mlcochova et al.\textsuperscript{17} reported that Delta variant had a higher replication efficiency in both 3D airway organoid and human airway epithelial organoids compared to Alpha variant. In COVID-19 patients, the time interval from exposure to the first PCR-positive test has shortened from 6 days during the 2020 epidemic to 4 days in the recent Delta variant epidemic, indicating the shorter incubation period of the Delta variant.\textsuperscript{18} Another outbreak in Guangdong Province in China also exerts a similar incubation period.\textsuperscript{19} The mean generation time and mean serial interval are 2.9 and 2.3 days, respectively, both of which are shorter than that of SARS-CoV-2 wild type (2.9 vs 5.7 for mean generation time and 2.3 vs 5.5 for mean serial interval).\textsuperscript{19,20} Additionally, 64.7\% (44/68) of transmission events by Delta variant occurred during the presymptomatic phase. But this percentage was 59.2\% in the first outbreak in Hubei Province.\textsuperscript{20} More importantly, the viral loads of Delta variant infections were on average approximately 1000 times greater than infections in the initial epidemic wave.\textsuperscript{18} In Scotland, the Delta variant was found mainly in younger people, and the risk of hospitalization was approximately doubled in those infected with Delta variant compared to Alpha variant infection.\textsuperscript{21} Likewise, a significantly increased risk of emergency care attendance or hospitalization was observed in the United Kingdom.\textsuperscript{16} Taken together, these transmission parameters suggest the probability of Delta variant becoming the dominant circulating lineages and indicate a significant challenge to battle against Delta variant.

Several properties of the Delta variant have been analyzed to explain why Delta broke through a variety of variants. On the one hand, the Delta variant spike fuses more efficiently with target cells with low human angiotensin-converting enzyme 2 (hACE2) level than other variants, and its pseudovirus infects target cells significantly faster than other variants.\textsuperscript{22} This evolutionary optimization of efficient fusion may explain why Delta variant can rapidly attack more cells and spread from person to person in a rather short exposure time. On the other hand, structural analysis of receptor-binding domain RBD-ACE2 interface reveals that a total of 17 residues in RBD have four substitutions (L452R, D614G, P681R, and D950N) with B.1.617 and its sublineage and harbors additional five mutations (T19R, Δ156-Δ157, R158G, and T478K).\textsuperscript{24,25} Presently, all the circulating SARS-CoV-2 variants evolve based on D614G that is involved in high transmissibility and infectivity but not in disease severity.\textsuperscript{26–32} L452 residue is located on the edge of the receptor-binding motif (RBM) of RBD and can directly contact with ACE2. It is necessary
for the hydrophobicity with L492 that forms another hydrophobic interaction with F490. L452R substitution enhances viral infectivity and fusion efficacy as well as viral replication. P681 is located at the unique “PRRAR” furin cleavage sites at the S1-S2 boundary of the spike. It plays an important role in facilitating the transmission of variants between humans. P681R substitution in spike optimizes the furin cleavage site and enables more efficient spike cleavage by furin, resulting in augmented syncytium formation and consequently enhanced transmissibility and pathogenicity. D950 located in heptad repeat 1 (HR1) of S2 subunit where is a critical site that can influence the refolding of S2. D950 is required for the fusion of SARS-CoV-2 and host cell membranes. D950N mutation eliminates a negative charge, which shows no obvious influence on spike structure but might enhance fusogenicity of the Delta spike. Collectively, these mutations in the Delta spike work together and finally improve its fitness advantages, pathogenicity, and infectivity.

3 IMMUNE EVASION OF DELTA VARIANT

The double mutations of E484Q and L452R in the spike of B.1.617 lineages had caused global concerns since E484
### Table 1

The effectiveness of current COVID-19 vaccines against the Delta variant

| Name (company)       | Antigen                                                                 | VE against wild type | Measure outcome                      | 1st Dose VE (95% CI) | 2nd Dose VE (95% CI) | Country | References (Date) |
|----------------------|--------------------------------------------------------------------------|----------------------|--------------------------------------|---------------------|---------------------|---------|-------------------|
| BNT162b2 (Pfizer-BioNTech) | Full-length spike protein with proline substitutions | 95%                  | Symptomatic COVID-19                 | 35.6% (22.7-46.4)   | 88% (85.3-90.1)     | UK      | (July 21, 2021)   |
|                      |                                                                         |                      | Symptomatic infection                | 56% (45-64)         | 87% (64-95)         | Canada  | (July 3, 2021)    |
|                      |                                                                         |                      | Hospitalization or death             | 78% (65-86)         | —                   |         |                   |
|                      |                                                                         |                      | Hospitalization                      | 94% (46-99)         | 96% (86-99)         | UK      | (June 14, 2021)   |
|                      |                                                                         | 94.1%                | Symptomatic infection                | 72% (57-82)         | —                   | Canada  | (July 3, 2021)    |
|                      |                                                                         |                      | Hospitalization or death             | 96% (72-99)         | —                   |         |                   |
| mRNA-1273 (Moderna)  | Full-length spike protein with proline substitutions                    | 94.1%                | Symptomatic COVID-19                 | 30% (24.3-35.3)     | 67% (61.3-71.8)     | UK      | (July 21, 2021)   |
|                      |                                                                         |                      | Symptomatic infection                | 67% (44-80)         | —                   | Canada  | (July 3, 2021)    |
|                      |                                                                         |                      | Hospitalization or death             | 88% (60-96)         | —                   |         |                   |
|                      |                                                                         |                      | Hospitalization                      | 71% (51-83)         | 92% (75-97)         | UK      | (June 4, 2021)    |
|                     |                                                                         |                      | Documented infection                 | 18% (9-25)          | 60% (53-66)         | Scotland| (June 14, 2021)   |
|                      |                                                                         |                      | Symptomatic infection                | 32.9% (19.3-44.3)   | 59.8% (28.9-77.3)   | UK      | (May 20, 2021)    |

Data were collected from WHO and PubMed. VE, vaccine effectiveness; UK, the United Kingdom.

A mutation appeared in the rapidly spreading variants Beta and Gamma and was associated with immune evasion.5,37 Previous studies reported that E484 residue was theoretically recognized as a repulsive residue at the RBD-ACE2 interface, and mutation at this site would be beneficial to RBD-ACE2 binding.38 More importantly, E484 and L452 mutations are involved in impaired neutralization by antibodies.39,40 Therefore, B.1.617, B.1.617.1, and B.1.617.3 variants with E484 and L452 mutations were initially considered to be strongly resistant to the immune response of the body. However, recent evidence has revealed that the majority of sera from convalescents and vaccinated individuals can neutralize B.1.617 and B.1.617.1 variants, and the reduction of neutralizing ability is limited to 2-fold. Delta variant is 5.7- and 8-fold less sensitive to the sera from convalescent and vaccinated individuals compared to the SARS-CoV-2 wild type.17,41–43 The sera from COVID-19 convalescents were 4-fold less potent against Delta variant when compared with that of the Alpha variant, which was similar to the Beta variants.7 Moreover, sera from individuals vaccinated one dose of Pfizer or AstraZeneca vaccine showed poor neutralization against the Delta variant. A total of 95% of individuals who obtained full vaccination generated a neutralizing response against the Delta variant but the titers were 3- to 5-fold lower than against the Alpha variant.7 In several clinical trials, the adjusted vaccine effectiveness (VE) against infection among those fully vaccinated declined about 20% for mRNA vaccine and adenovirus vector vaccine ChAdOx1.21,44 The effectiveness of the present COVID-19 vaccines against the Delta variant is summarized in Table 1. Notably, a recent study demonstrated that there was no difference in viral loads between unvaccinated individuals and fully vaccinated individuals, who also can be infected with Delta variant, 33% (26/79) of who infected with Delta variant showed $Ct$ value below 20.45
Meanwhile, the Delta variant exerts resistance to some anti-N-terminal domain and anti-RBD therapeu-
tic monoclonal antibodies for COVID-19 including Bamlanivimab. But three other clinically approved
monoclonal antibodies Etesivimab, Basirivimab, and Imdevimab preserved neutralization ability against
the Delta variant. Besides, using a cocktail of multiple neutral-
izing antibodies that recognize and bind to different and
nonoverlapping epitopes of the spike could restrict the
potential loss of single antibody-mediated neutralization
and minimize the possible generation of viral escape
mutants. The RBM epitopes in RBD that overlap with ACE2
are immunodominant. T478, E484, and L452 residues are
located in immunodominant RBM epitopes and could
influence the binding ability by antibodies from serum or
some therapeutic antibodies. L452R substitution abol-
ishes the hydrophobic interaction with I and V105 residues
of the antibody’s heavy chain, resulting in impaired neu-
tralization of RBD-specific mAbs. Besides, L452R muta-
tion makes a different conformation of epitope peptide,
which weakens binding affinity of spike and ACE2 and
reduces suboptimal recognition by T-cell receptor and
thereby escape human leukocyte antigen-restricted cellular
immunity. The T478K is a unique substitution in the
Delta variant. It falls within the epitope region of potential
“Class 1” neutralizing monoclonal antibodies that bind
the spike protein in the open conformation. However, the
mechanism of T478K mutation affecting immune escape
remains unclear. Further studies are required to determine
its impact. Nonetheless, these novel mutations, including
L452R, T478K, and P681R should be seriously considered
when developing next-generation vaccines or monoclonal
antibodies in the future.

4 | PERSPECTIVES OF STRATEGIES AGAINST DELTA VARIANT

4.1 | Physical protection

WHO has advocated some precautions to protect us from
COVID-19, such as cleaning hands, wearing a mask, keep-
ing rooms well ventilated, etc., especially for healthcare
workers (HCWs) who are not only in close contact with
COVID-19 patients, but also in a poorly ventilated environ-
ment. Previous studies have shown that the infection rates
of SARS-CoV-2 among HCWs range 2.2–44% which is sig-
nificantly higher than that of the general population. Therefore, FFP2/3 respirators or similar respirators are rec-
ommended to replace surgical masks when HCWs contact
with confirmed or suspected COVID-19 patients to avoid
the secondary transmission, especially in the face of highly
infectious variants as Delta. Moreover, workers with
occupational exposure to SARS-CoV-2 should be encour-
aged to conduct frequent tests to limit virus spread.

4.2 | Optimizing vaccination program

Studies have demonstrated that pre-existing cellular
immunity in people infected by other coronaviruses
might contribute to the different disease severity between
COVID-19 patients, which might partly explain the
fully vaccinated individuals exert more mild-moderate
phenotypes of COVID-19 compared to unvaccinated
individuals. Similarly, although reduction of VE against
Delta variant has been observed in several studies, the
current vaccines remain protective against Delta variant. For example, household members who received at least
one dose of vaccine were 50% less likely to be infected
by SARS-CoV-2 than unvaccinated members. Among
outbreak-associated COVID-19 patients in central Okla-
homa, 85% (40/47) had never received any COVID-19
vaccine doses, and 6% (3/47) and 9% (4/47) had received
one dose and two doses of Moderna or Pfizer-BioNTech
vaccines. These results indicate that vaccination remains
an effective measure to avoid Delta variant infection.
The development of specific vaccines based on the Delta
spike can effectively improve the protection efficiency of
vaccines. Before the use of Delta-specific vaccine, opti-
mization of our vaccination program may be an effective
strategy to enhance the VE against Delta variant. Using a
combination of a DNA vaccine and a recombinant S1 sub-
unit vaccine induced high levels of nAbs as well as strong
T-cell immune responses to protect rhesus macaques
after the challenge of SARS-CoV-2 viruses, which is better
than administration DNA or protein vaccine alone. And
Georg Behrens, an immunologist at Hanover Medical
School in Germany, pointed out that vaccination with
different types of vaccines could trigger a better overall
response to increase the effectiveness. Moreover, oral and nasal mucosae serve as the primary
defense to prevent pathogens from entry and infection. Evidence and lessons from SARS-CoV and MERS-CoV
indicate that activation mucosal immune response is a
comprehensive strategy to suppress SARS-CoV-2 infec-
tion, especially in the face of Delta variant that shows less
resistance to vaccines compared to Beta variant but exerts
prominent transmissibility and infectivity. Therefore,
developing COVID-19 vaccines that could elicit a strong
immune response at both mucosal sites and systemic cir-
culation might be a promising approach to suppress the
infection and transmission of the Delta variant.
5 | CONCLUSIONS

Mutations will occur in the future due to natural selection, random genetic drift, or influence of the environment.66 Some other variants have appeared, such as Lambda (C.37), Mu (B.1.621), Theta (P.3), etc. Effective caution and protective measures should be taken to ensure safe contacts to suppress the spread of SARS-CoV-2. Genomic surveillance of COVID-19 patients, especially vaccine breakthrough cases, will be essential to monitor the evolution of SARS-CoV-2. Developing safe and effective vaccines and a global vaccination programme are necessary strategies to tackle or eliminate the COVID-19 pandemic.

ACKNOWLEDGMENTS

This work was supported by the Excellent Youth Foundation of the Sichuan Scientific Committee Grant in China (No. 2019JDQK008), National Natural Science Foundation Regional Innovation and Development (No. U19A2003), and the National Natural Science Foundation of China (No. 81800421). Figures are created by Biorender.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

AUTHORS’ CONTRIBUTIONS

Xiawei Wei and Kang Zhang conceived the study and revised the manuscript. Xuemei He, Cai He, and Weiqi Hong wrote the article.

DATA AVAILABILITY STATEMENT

The data included in this study are available upon request from the corresponding author.

ETHICS STATEMENT

Not applicable.

ORCID

Weiqi Hong https://orcid.org/0000-0003-1668-2301
Xiawei Wei https://orcid.org/0000-0002-6513-6422

REFERENCES

1. Ke Z, Oton J, Qu K, et al. Structures and distributions of SARS-CoV-2 spike proteins on intact virions. Nature 2020;588(7838):498-502.
2. Bakhshandeh B, Jahanafooz Z, Abbasi A, et al. Mutations in SARS-CoV-2: consequences in structure, function, and pathogenicity of the virus. Microb Pathog. 2021;154:104831.
3. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020;395(10224):565-574.
4. Canton R, De Lucas Ramos P, Garcia-Botella A, et al. New variants of SARS-CoV-2. Rev Esp Quimioter. 2021. http://doi.org/10.37201/req/071.2021
5. Cherian S, Potdar V, Jadhav S, et al. Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India. bioRxiv 2021. https://doi.org/10.1101/2021.04.22.440932
6. Winger A, Caspari T. The spike of concern—the novel variants of SARS-CoV-2. Viruses 2021;13(6):1002.
7. Planas D, Veyer D, Baidaliuk A, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 2021;596(7871):276-280.
8. Cascella M, Rajnik M, Aleem A. In: StatPearls, ed. Features, Evaluation, and Treatment of Coronavirus (COVID-19). FL: StatPearls Publishing; 2021.
9. Brand SPC, Ojal J, Aziza R, et al. COVID-19 transmission dynamics underlying epidemic waves in Kenya. medRxiv 2021. https://doi.org/10.1101/2021.06.17.21259100
10. Baral P, Bhattacharai N, Hossen ML, et al. Mutation-induced changes in the receptor-binding interface of the SARS-CoV-2 Delta variant B.1.617.2 and implications for immune evasion. bioRxiv 2021. https://doi.org/10.1101/2020.07.17.452576
11. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382(13):1199-1207.
12. Zhang S, Diao M, Yu W, Pei L, Lin Z, Chen D. Estimation of the reproductive number of novel coronavirus (COVID-19) and the probable outbreak size on the diamond princess cruise ship: a data-driven analysis. Int J Infect Dis. 2020;93:201-204.
13. Liu J, Liu Y, Xia H, et al. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature 2021;596(7871):273-275.
14. Campbell F, Archer B, Laurensen-Schafer H, et al. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. Euro Surveill. 2021;26(24):2100509.
15. Dougherty K, Mannell M, Naqvi O, Matson D, Stone J. SARS-CoV-2 B.1.617.2 (Delta) variant COVID-19 outbreak associated with a gymnastics facility—Oklahoma, April-May 2021. MMWR Morb Mortal Wkly Rep. 2021;70(28):1004-1007.
16. Alizon S, Haim-Boukoba Z, Fouloungne V, et al. Rapid spread of the SARS-CoV-2 Delta variant in some French regions, June 2021. Euro Surveill. 2021;26(28):2100573.
17. Mlcocova P, Kemp S, Dhar MS, et al. SARS-CoV-2 B.1.617.2 Delta variant emergence, replication and sensitivity to neutralising antibodies. bioRxiv 2021. https://doi.org/10.1101/2021.05.08.443253
18. Li B, Deng A, Li K, et al. Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 Delta variant. medRxiv 2021. https://doi.org/10.1101/2021.07.07.21260122
19. Zhang M, Xiao J, Deng A, et al. Transmission dynamics of an outbreak of the COVID-19 Delta variant B.1.617.2—Guangdong Province, China, May-June 2021. China CDC Weekly. 2021;3(27):584-586.
20. Hu S, Wang W, Wang Y, et al. Infectivity, susceptibility, and risk factors associated with SARS-CoV-2 transmission under intensive contact tracing in Hunan, China. Nat Commun. 2021;12(1):1533.
21. Sheikh A, McMenamin J, Taylor B, Robertson C, Public Health Scotland, the EICC. SARS-CoV-2 Delta VOC in Scotland:
demographics, risk of hospital admission, and vaccine effectiveness. *Lancet* 2021;397(10293):2461-2462.

22. Zhang J, Xiao T, Cai Y, et al. Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant. *bioRxiv* 2021. https://doi.org/10.1101/2021.08.17.456689

23. Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. *Nature* 2020;581(7807):215-220.

24. Yadav PD, Sapkal GN, Abraham P, et al. Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees. *Clin Infect Dis*. 2021.

25. Francisco RDS Jr, Benites LF, Lamarca AP, et al. Pervasive transmission of E484K and emergence of VUI-NP13L with evidence of SARS-CoV-2 co-infection events by two different lineages in Rio Grande do Sul, Brazil. *Virus Res*. 2021;296:198345.

26. Zhang L, Jackson CB, Mou H, et al. SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. *Nat Commun*. 2020;11(1):6013.

27. Mittal A, Verma V. Connections between biomechanics and higher infectivity: a tale of the D614G mutation in the SARS-CoV-2 spike protein. *Signal Transduct Target Ther*. 2021;6(1):11.

28. Korber B, Fischer WM, Gnanakaran S, et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. *Cell* 2020;182(4):812-827.

29. Plante JA, Liu Y, Liu J, et al. Spike mutation D614G alters SARS-CoV-2 fitness. *Nature* 2021;592(7852):116-121.

30. Yurkovetskiy L, Wang X, Pascal KE, et al. Comprehensive analysis of the D614G SARS-CoV-2 spike protein variant. *Cell* 2020;183(3):739-751.

31. Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science* 2020;367(6483):1260-1263.

32. Benton DJ, Wrobel AG, Roustan C, et al. The effect of the D614G substitution on the structure of the spike glycoprotein of SARS-CoV-2. *Proc Natl Acad Sci USA*. 2021;118(9):e2022586118.

33. Greaney AJ, Loes AN, Crawford KHD, et al. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. *Cell Host Microbe*. 2021;29(3):463-476.

34. Motozono C, Toyoda M, Zahradnik J, et al. SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity. *Cell Host Microbe*. 2021;29(7):1124-1113.

35. Peacock TP, Sheppard CM, Brown JC, et al. The SARS-CoV-2 variants associated with infections in India, B.1.617, show enhanced spike cleavage by furin. *bioRxiv* 2021. https://doi.org/10.1101/2021.05.28.446163

36. Ferreira I, Datir R, Kemp S, et al. SARS-CoV-2 B.1.617 emergence and sensitivity to vaccine-elicited antibodies. *bioRxiv* 2021. https://doi.org/10.1101/2021.05.08.443253

37. Jangra S, Ye C, Rathnasinge R, et al. SARS-CoV-2 spike E484K mutation reduces antibody neutralisation. *Lancet Microbe* 2021;2(7):e283-e284.

38. Yang Y, Zhang Y, Qu Y, et al. Key residues of the receptor binding domain in the spike protein of SARS-CoV-2 mediating the interactions with ACE2: a molecular dynamics study. *Nanoscale* 2021;13(20):9364-9370.

39. Tegally H, Wilkinson E, Giovanetti M, et al. Detection of a SARS-CoV-2 variant of concern in South Africa. *Nature* 2021;592(7854):438-443.

40. Khan A, Zia T, Suleman M, et al. Higher infectivity of the SARS-CoV-2 new variants is associated with K417N/T, E484K, and N501Y mutants: an insight from structural data. *J Cell Physiol*. 2021;236(10):7045-7057.

41. Yadav PD, Sapkal GN, Abraham P, et al. Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees. *bioRxiv* 2021. https://doi.org/10.1101/2021.04.23.441101

42. Liu Y, Liu J, Xia H, et al. Neutralizing activity of BNT162b2-elicted serum. *N Engl J Med*. 2021;384(15):1466-1468.

43. Edara VV, Pinsky BA, Suthar MS, et al. Infection and vaccine-induced neutralizing-antibody responses to the SARS-CoV-2 B.1.617 variants. *N Engl J Med*. 2021;385(7):664-666.

44. Bernal JL, Andrews N, Gower C, et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. *medRxiv* 2021. https://doi.org/10.1101/2021.05.22.21227658

45. Riemersma KK, Grogan BE, Kita-Yarbro A, et al. Vaccinated and unvaccinated individuals have similar viral loads in communities with a high prevalence of the SARS-CoV-2 delta variant. *medRxiv* 2021. https://doi.org/10.1101/2021.07.31.21261387

46. Starr TN, Greaney AJ, Dingens AS, Bloom JD. Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. *Cell Rep Med*. 2021;2(4):100255.

47. Baum A, Fulton BO, WLOGA E, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. *Science* 2020;369(6506):1014-1018.

48. Jiang S, Hillyer C, Du L. Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses: (trends in immunology 41, 355–359; 2020). *Trends Immunol*. 2020;41(6):545.

49. Starr TN, Czudnochowski N, Liu Z, et al. SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. *Nature* 2021;597(7874):97-102.

50. McCallum M, Bassi J, Marco AD, et al. SARS-CoV-2 immune evasion by variant B.1.427/B.1.429. *bioRxiv* 2021. https://doi.org/10.1101/2021.03.31.437925

51. Zhang H, Deng S, Ren L, et al. Profiling CD8+ T cell epitopes of COVID-19 convalescents reveals reduced cellular immune responses to SARS-CoV-2 variants. *Cell Reports*. 2021;36:109708.

52. Harvey WT, Carabelli AM, Jackson B, et al. SARS-CoV-2 variants, spike mutations and immune escape. *Nat Rev Microbiol*. 2021;19(7):409-424.

53. Houlihan CF, Vora N, Byrne T, et al. Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health care workers’ COVID19 infections and related safety guidelines. *Lancet* 2020;396(10246):e6-e7.

54. Oksanen LAH, Sanmark E, Oksanen SA, et al. Sources of healthcare workers’ COVID19 infections and related safety guidelines. *Int J Occup Med Environ Health*. 2021;34(2):239-249.

55. Chu DK, Akl EA, Duda S, et al. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. *Lancet* 2020;395(10242):1973-1987.

56. Hetemaki I, Kaarainen S, Alho P, et al. An outbreak caused by the SARS-CoV-2 Delta variant (B.1.617.2) in a secondary care hospital in Finland, May 2021. *Euro Surveill*. 2021;26(30):2100636.
57. Le Bert N, Clapham HE, Tan AT, et al. Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection. J Exp Med. 2021;218(5):e20202617.
58. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. 2021;385(7):585-594.
59. Layan M, Gilboa M, Gonen T, et al. Impact of BNT162b2 vaccination and isolation on SARS-CoV-2 transmission in Israeli households: an observational study. medRxiv 2021. https://doi.org/10.1101/2021.07.12.21260377
60. Li Y, Bi Y, Xiao H, et al. A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques. Emerg Microbes Infect. 2021;10(1):342-355.
61. Sanderson K. COVID vaccines protect against Delta, but their effectiveness wanes. Nature 2021. https://doi.org/10.1038/d41586-021-02261-8
62. Moreno-Fierros L, Garcia-Silva I, Rosales-Mendoza S. Development of SARS-CoV-2 vaccines: should we focus on mucosal immunity? Expert Opin Biol Ther. 2020;20(8):831-836.
63. Mudgal R, Nehul S, Tomar S. Prospects for mucosal vaccine: shutting the door on SARS-CoV-2. Hum Vaccin Immunother. 2020;16(12):2921-2931.
64. King RG, Silva-Sanchez A, Peel JN, et al. Single-dose intranasal administration of AdCOVID elicits systemic and mucosal immunity against SARS-CoV-2 and fully protects mice from lethal challenge. Vaccines (Basel) 2021;9(8):881.
65. Russell MW, Moldoveanu Z, Ogra PL, Mestecky J. Mucosal immunity in COVID-19: a neglected but critical aspect of SARS-CoV-2 infection. Front Immunol. 2020;11:611337.
66. Grubaugh ND, Hanage WP, Rasmussen AL. Making sense of mutation: what D614G means for the COVID-19 pandemic remains unclear. Cell 2020;182(4):794-795.
67. Nasreen S, He S, Chung H, et al. Effectiveness of COVID-19 vaccines against variants of concern, Canada. medRxiv 2021. https://doi.org/10.1101/2021.06.28.21259420
68. Stoew J, Andrews N, Gower C, et al. Effectiveness of COVID-19 Vaccines Against Hospital Admission with the Delta (B.1.617.2) Variant. England: PHE Publishing; 2021. https://khub.net/documents/135939561/479607266/Effectiveness+of+COVID-19+vaccines+against+hospital+admission+with+the+Delta+%28B.1.617.2%29+variant.pdf/1c213463-3997-ed16-2a6f-14e5deb0b997?t=1623689315431
69. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021;397(10269):99-111.

How to cite this article: He X, He C, Hong W, Zhang K, Wei X. The challenges of COVID-19 Delta variant: Prevention and vaccine development. MedComm. 2021;2:846–854. https://doi.org/10.1002/mco2.95